Please note: The information displayed on this page might be outdated.
MiNa Therapeutics: Developer of therapeutic medicines designed to harness gene activation mechanisms through small activating RNA. The company's technology and clinical know-how transform the therapy landscape of cancer and other severe diseases, enabling doctors and physicians to cure cancer and other severe diseases and develop new medicines that restore normal function to patients' cells.
Phase l or ll
Immuno-Oncology, Oncology, Rare Disease
Company Participants at European Biotech Investor Days 2021
MiNa Therapeutics, Chief Executive Officer
Robert joined MiNA as Chief Executive Officer in 2013. In that period he has been the driving force in establishing MiNA’s strategy, financing, and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.